Perosphere Inc. Receives FDA IND Clearance to Initiate Clinical Investigations of the Safety and Efficacy of PER977 to Reverse the Activity of Anticoagulation Therapies Including Factor Xa- and IIa-Inhibitors
5/22/2013 11:07:24 AM
More...
|
Perosphere Inc. and Daiichi Sankyo, Inc. (4568.t) Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban
4/25/2013 10:49:34 AM
More...
|
Perosphere Inc. Launched -- First Close of $1.5 Million Series A Convertible Preferred Stock Offering
12/19/2011 7:31:39 AM
More...
|